Cytek Biosciences, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q4 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Cytek Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q4 2024.
Cytek Biosciences, Inc. Debt-to-equity for the quarter ending December 31, 2024 was 25.8 %, a 5% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2024	25.8	+1.23	+5%	Dec 31, 2024
Q3 2024	25.7	+2.04	+8.62%	Sep 30, 2024
Q2 2024	25.1	+2.7	+12%	Jun 30, 2024
Q1 2024	25	+3.51	+16.4%	Mar 31, 2024
Q4 2023	24.6	+4.31	+21.2%	Dec 31, 2023
Q3 2023	23.7	+5.34	+29.1%	Sep 30, 2023
Q2 2023	22.4	+5.87	+35.5%	Jun 30, 2023
Q1 2023	21.4	+1.99	+10.2%	Mar 31, 2023
Q4 2022	20.3			Dec 31, 2022
Q3 2022	18.3			Sep 30, 2022
Q2 2022	16.5			Jun 30, 2022
Q1 2022	19.5			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.